Cardio Diagnostics Holdings, Inc. is a US-listed company in the health care equipment industry. Its financial year ends in December.
Loading chart…
Third-party market data · may be delayed
Under review: data-quality checks not passed.
Under review: data-quality checks not passed. We'll show the comparison once resolved.
Cardio Diagnostics Holdings, Inc. valuation: adjust assumptions and compare models →
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
Cardio Diagnostics has little or no product revenue yet; it used $6m of cash in the twelve months to June 2026. It passes 2 of our 3 financial-health checks.
Our model value for Cardio Diagnostics Holdings is under review, so past values are not shown until it is resolved.
Source: 10-Q filed August 7, 2026 on SEC EDGAR · Financials · Valuation
Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.
Cardio Diagnostics Holdings, Inc.'s trailing-twelve-month revenue fell 25.9% year on year, with a free-cash-flow margin of -40307.5%.
Current signal Capital expenditure surging: TTM capex grew 220% year over year and now absorbs 1139.1% of revenue.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Nothing in Cardio Diagnostics Holdings, Inc.'s latest figures clears our strength thresholds.
Loading chart…
Third-party market data · may be delayed
Company announcements, filed results and changes that matter to shareholders.
| At fiscal year end | 2022 | 2023 | 2024 | 2025 | Now |
|---|---|---|---|---|---|
| Share price | $31.80 | $74.70 | $27.51 | $2.71 | $1.67 |
| Market value | $26m | $63m | $49m | $5m | $4m |
| + Net debt (− = net cash) | $0 | $0 | $0 | $0 | $0 |
| Enterprise value | $26m | $63m | $49m | $5m | $4m |
| Multiples | |||||
| Price / sales | n/m | n/m | n/m | n/m | n/m |
| Price / earnings | — | — | — | — | — |
| Price / free cash flow | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — |
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Low.
Next results: November 6, 2026, after the close.
No analyst estimates are published for Cardio Diagnostics Holdings, Inc.: too few analysts cover it.
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Mar 2025 | −$1.80 | −$0.97 | +46.1% |
| Dec 2024 | −$1.80 | −$0.30 | +83.3% |
| Sept 2024 | −$1.50 | −$1.80 | −20.0% |
| Jun 2024 | −$2.70 | −$1.80 | +33.3% |
Adjusted EPS as companies report it, against the average analyst estimate.
Last 12 months −58.7%
| Part | Then | Now | Effect |
|---|---|---|---|
| Revenue (last 12 months) | $19507 | $14450 | −25.9% |
| P/S multiple | n/m | n/m | −20.2% |
| Share count | 2m | 2m | −30.0% |
Biggest factor: share count. Loss-making at one end, so the split uses price/sales.
| Calendar year | 2023 | 2024 | 2025 | 2026 to date |
|---|---|---|---|---|
| Return | ||||
| CDIO | +135% | −63% | −90% | −38% |
| Industry peers (median) | −9% | −19% | −16% | −13% |
| S&P 500 | +26% | +25% | +18% | +11% |
| Months that ended higher | ||||
| CDIO | 42% | 33% | 42% | 46% |
| S&P 500 | 67% | 75% | 75% | 46% |
| Largest fall from a high during the year | ||||
| CDIO | −98% | −93% | −91% | −79% |
| S&P 500 | −10% | −8% | −19% | −9% |
Worst fall since January 14, 2022: 100% from October 17, 2022 to February 5, 2026. Getting back needed a 29186% gain, and the shares have not yet recovered.
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | Revenue (TTM) |
|---|---|
| FY23 Q3 | $12.7K |
| FY23 Q4 | $17.1K |
| FY24 Q1 | $33K |
| FY24 Q2 | $39.1K |
| FY24 Q3 | $35.7K |
| FY24 Q4 | $34.9K |
| FY25 Q1 | $19.9K |
| FY25 Q2 | $19.5K |
| FY25 Q3 | $15.8K |
| FY25 Q4 | $14.8K |
| FY26 Q1 | $16.6K |
| FY26 Q2 | $14.5K |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | Revenue growth, TTM YoY |
|---|---|
| FY23 Q4 | 1696.3% |
| FY24 Q1 | 3372.9% |
| FY24 Q2 | 1363.1% |
| FY24 Q3 | 180.9% |
| FY24 Q4 | 104.5% |
| FY25 Q1 | -39.7% |
| FY25 Q2 | -50.2% |
| FY25 Q3 | -55.8% |
| FY25 Q4 | -57.5% |
| FY26 Q1 | -16.8% |
| FY26 Q2 | -25.9% |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | Operating margin (TTM) |
|---|---|
| FY23 Q3 | -63585.3% |
| FY23 Q4 | -42440.4% |
| FY24 Q1 | -29392.2% |
| FY24 Q2 | -21530.7% |
| FY24 Q3 | -23513.4% |
| FY24 Q4 | -23977.9% |
| FY25 Q1 | -29335.7% |
| FY25 Q2 | -31961.0% |
| FY25 Q3 | -41422.2% |
| FY25 Q4 | -43737.5% |
| FY26 Q1 | -40074.6% |
| FY26 Q2 | -44690.7% |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | FCF margin (TTM) |
|---|---|
| FY24 Q2 | -15103.6% |
| FY24 Q3 | -16909.5% |
| FY24 Q4 | -14926.5% |
| FY25 Q1 | -26935.6% |
| FY25 Q2 | -28567.1% |
| FY25 Q3 | -37690.0% |
| FY25 Q4 | -39893.1% |
| FY26 Q1 | -36657.0% |
| FY26 Q2 | -40307.5% |
| Fiscal year | 2021 Dec 2021 | 2022 Dec 2022 | 2023 Dec 2023 | 2024 Dec 2024 | 2025 Dec 2025 | LTM Jun 2026 |
|---|---|---|---|---|---|---|
| Income | ||||||
| Revenue | 1 | 1 | 17 | 35 | 15 | 14 |
| EBITDA | −604 | −4,532 | −7,223 | −8,346 | −6,419 | −6,457 |
| Operating income | −620 | −4,548 | −7,242 | −8,366 | −6,484 | −6,458 |
| Net income | −620 | −4,661 | −8,377 | −8,383 | −6,498 | −6,470 |
| Diluted EPS | −$1.99 | −$5.66 | −$9.90 | −$4.67 | −$3.71 | −$2.76 |
| Growth (year on year) | ||||||
| Revenue | — | +5.4% | +>999% | +104.5% | −57.5% | −25.9% |
| Margins | ||||||
| EBITDA margin | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% |
| Operating margin | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% |
| Net margin | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% |
| Free-cash-flow margin | — | — | <−999% | <−999% | <−999% | <−999% |
| Cash flow | ||||||
| Cash from operations | −585 | −5,091 | −5,672 | −4,993 | −5,727 | −5,660 |
| Capital spending | — | — | 576 | 215 | 187 | 165 |
| Free cash flow | — | — | −6,248 | −5,208 | −5,914 | −5,824 |
| Stock-based pay | 60 | 0 | 1,279 | 2,591 | 110 | 98 |
| Free cash flow after stock pay | — | — | −7,527 | −7,799 | −6,024 | −5,922 |
| Balance sheet | ||||||
| Cash | 0 | 0 | 0 | 0 | 0 | 0 |
| Total debt | — | 0 | 0 | 0 | 0 | 0 |
| Net debt (negative = net cash) | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted shares | — | — | — | 2m | 2m | 2m |
| Quarter | 2024 Q3 Sept 2024 | 2024 Q4 Dec 2024 | 2025 Q1 Mar 2025 | 2025 Q2 Jun 2025 | 2025 Q3 Sept 2025 | 2025 Q4 Dec 2025 | 2026 Q1 Mar 2026 | 2026 Q2 Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Income | ||||||||
| Revenue | 7 | 5 | 1 | 7 | 3 | 4 | 3 | 5 |
| EBITDA | −1,404 | −1,511 | −1,585 | −1,670 | −1,671 | −1,514 | −1,779 | −1,493 |
| Operating income | −1,409 | −1,516 | −1,631 | −1,679 | −1,712 | −1,463 | −1,785 | −1,498 |
| Net income | −1,413 | −1,519 | −1,635 | −1,683 | −1,715 | −1,465 | −1,788 | −1,501 |
| Diluted EPS | −$1.73 | −$0.28 | −$0.97 | −$0.97 | −$0.98 | −$0.80 | −$0.63 | −$0.51 |
| Growth (year on year) | ||||||||
| Revenue | −34.4% | −15.0% | −94.1% | −5.0% | −56.6% | −21.2% | +185.1% | −28.3% |
| Margins | ||||||||
| EBITDA margin | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% |
| Operating margin | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% |
| Net margin | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% |
| Free-cash-flow margin | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% |
| Cash flow | ||||||||
| Cash from operations | −1,157 | −1,392 | −1,400 | −1,571 | −1,393 | −1,362 | −1,562 | −1,342 |
| Capital spending | 23 | 4 | 6 | 19 | 163 | 0 | 2 | 0 |
| Free cash flow | −1,181 | −1,396 | −1,406 | −1,590 | −1,556 | −1,362 | −1,564 | −1,342 |
| Stock-based pay | 23 | 22 | 31 | 31 | 25 | 24 | 25 | 24 |
| Free cash flow after stock pay | −1,203 | −1,418 | −1,437 | −1,621 | −1,581 | −1,386 | −1,589 | −1,367 |
| Last 12 months unless stated | CDIO | CUPR | HSCS | POAS | PAVM | NXL | Median |
|---|---|---|---|---|---|---|---|
| Revenue, last 12 months | $14450 | $38204 | $4519 | $102806 | $112000 | $217155 | $95m |
| Revenue growth, last 12 months | −25.9% | 5.6% | −64.2% | −18.2% | −89.0% | 24.2% | 9.1% |
| Revenue growth, 3-year average | 75.5% | — | — | — | −49.6% | −30.6% | 14.0% |
| Revenue growth, latest quarter | −28.3% | — | 10.5% | — | 450.0% | −82.8% | 9.9% |
| Gross margin | — | −1.3% | 60.9% | 13.1% | −220.5% | 86.2% | 61.2% |
| Operating margin | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | −8.7% |
| Operating margin, 3-year average | <−999% | — | <−999% | — | <−999% | <−999% | −17.9% |
| Net margin | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | −12.1% |
| Cash from operations / revenue | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | −2.1% |
| Free-cash-flow margin | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | −4.0% |
| Free-cash-flow margin, 3-year average | <−999% | — | — | — | <−999% | <−999% | −7.7% |
| Stock pay / revenue | 677.7% | — | >999% | — | >999% | >999% | 6.3% |
| Change in share count | — | 13.7% | 200.7% | 19.7% | 14.0% | 52.1% | 4.0% |
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Renaissance Technologies LLC | $107,748 | 49K | 25.5% | ▲ 220.6% |
| Blackrock, Inc. | $76,011 | 35K | 18.0% | 0.0% |
| Geode Capital Management, LLC | $57,449 | 26K | 13.6% | ▼ 18.5% |
| Vanguard Capital Management LLC | $44,139 | 20K | 10.4% | 0.0% |
| Citadel Advisors LLC | $41,765 | 19K | 9.9% | New |
| Xtx Topco Ltd | $35,244 | 16K | 8.3% | New |
| Jane Street Group, LLC | $26,133 | 12K | 6.2% | ▼ 85.3% |
| State Street Corp | $22,117 | 10K | 5.2% | New |
| Vanguard Fiduciary Trust Co | $6,185 | 3K | 1.5% | ▼ 28.8% |
| Tower Research Capital LLC (TRC) | $3,962 | 2K | 0.9% | ▼ 17.5% |
| UBS Group AG | $1,437 | 1K | 0.3% | ▼ 93.4% |
| Wolverine Asset Management LLC | $228 | 0K | 0.1% | 0.0% |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Cardio Diagnostics Holdings, Inc.'s complete shareholder register. Values are as reported by the filers .
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| Financial statements | SEC 10-K and 10-Q filings | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
New research on the companies we cover arrives in the weekly email. Free, one email a week.
